MedTrace Logo

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

NCT03410615 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2026-03-24

No results posted yet for this study

Summary

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards

Conditions

  • Oropharyngeal Squamous Cell Carcinoma

Interventions

RADIATION

Radiation

70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)

DRUG

Cisplatin

100 mg/m2 days 1, 22, 43 concurrently with RT

DRUG

Durvalumab

Given in concurrent and adjuvant phase

DRUG

Tremelimumab

ARM CLOSED TO ACCRUAL - 2019

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Anna Spreafico · UNH/Princess Margaret Cancer Centre, Toronto ON Canada

  • Khalil Sultanem · The Jewish General Hospital, Montreal QC, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-28
Primary Completion
2026-01-09
Completion
2026-07-31

Countries

  • Belgium
  • Canada
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03410615 on ClinicalTrials.gov